Should You Get a Multi-Cancer Early Detection Blood Test?

A new generation of blood tests promises to detect dozens of cancers with a single tube of blood. Tests such as Galleri and Cancerguard are part of a rapidly growing field called multi-cancer early detection (MCED) testing. The idea is appealing: find cancer earlier, treat it sooner, and save lives.

But as with many exciting medical advances, the reality is more complicated than the marketing.

MCED tests look for tiny fragments of tumor DNA circulating in the bloodstream. Unlike traditional screening tests—which look for one cancer at a time, such as mammograms for breast cancer or colonoscopy for colon cancer—these blood tests claim to screen for more than 50 different cancers at once. Some of those cancers currently have no standard screening test available.
 
That sounds revolutionary, and in some ways it may eventually become so. The technology behind these tests is impressive, and early studies suggest they can sometimes detect cancers before symptoms appear. In some cases, the test can even predict where in the body the cancer signal may be coming from.

However, there are several important reasons for caution.

First, no MCED test has yet been shown to improve survival or help people live longer. That is the key question in cancer screening. Detecting cancer earlier only matters if earlier detection changes outcomes. Right now, there are no completed outcome studies proving that these tests reduce cancer deaths or improve quality of life. Even supporters of the technology acknowledge that these studies will take years to complete.
 
Second, false positives are real. A positive MCED test does not mean you definitely have cancer. It often leads to additional CT scans, PET scans, biopsies, specialist visits, and anxiety while doctors search for a cancer that may not actually exist.

False negatives are also a concern. Some patients may incorrectly assume that a “no cancer signal detected” result means they are cancer-free and delay standard screenings or ignore symptoms. That would be a mistake. MCED tests are not replacements for mammograms, colonoscopy, Pap smears, low-dose lung CT scans, or other proven screening tests.
 
Cost is another issue. These tests are expensive and usually not covered by insurance or Medicare. Current pricing is approximately $949 for Galleri and about $689 for Cancerguard, not including possible follow-up testing.

For now, my recommendation is cautious skepticism. MCED testing is promising technology, and ongoing research may eventually show meaningful benefit. But today we simply do not have evidence that routine testing improves outcomes enough to justify the cost, uncertainty, and potential downstream harms.

The best approach remains surprisingly traditional: don’t smoke, maintain a healthy weight, exercise regularly, and stay up to date with proven cancer screening tests that already have strong evidence behind them.